Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients

doi:10.1007/s11684-020-0738-0

Front. Med.

2021, Vol. 15

Issue (4) : 621-628 https://doi.org/10.1007/s11684-020-0738-0

RESEARCH ARTICLE

Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients

Jiayi Wu, Weiqi Gao, Xiaosong Chen, Chunxiao Fei, Lin Lin, Weiguo Chen, Ou Huang, Siji Zhu, Jianrong He, Yafen Li, Li Zhu, Kunwei Shen(

)

Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Download: PDF(305 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Multi-gene assays have emerged as crucial tools for risk stratification in early-stage breast cancer. This study aimed to evaluate the prognostic significance of the 21-gene recurrence score (RS) in Chinese patients with pN0-1, estrogen receptor-positive (ER⁺), human epidermal growth factor receptor 2-negative (HER2^–) breast cancer. Among 800 patients recruited between 2009 and 2016, the median RS was 24 (0–69), with 27.4%, 46.8%, and 25.9% patients classified into low-, intermediate-, and high-risk groups. Cox regression analysis demonstrated that the high-risk category was associated with significantly higher odds of invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) events compared with the low-risk category (IDFS: HR= 2.450, 95% CI 1.017–5.902, P= 0.046; DDFS: HR= 2.829, 95% CI 1.013–7.901, P= 0.047). No significant association between RS category and overall survival (OS) was found (intermediate vs. low: HR= 1.244, 95% CI 0.292–5.297, P= 0.768; high vs. low: HR= 2.933, 95% CI 0.759–11.327, P= 0.119). RS, as a continuous variable, was a highly significant predictor for IDFS (HR= 1.028, 95% CI 1.010–1.047, P= 0.002), DDFS (HR= 1.030, 95% CI 1.010–1.051, P= 0.003), and OS (HR= 1.034, 95% CI 1.007–1.063, P= 0.014). Our findings suggested that RS may predict IDFS in Chinese patients with ER⁺/HER2^– breast cancer with N0 or N1 disease.

Keywords early breast cancer 21-gene assay recurrence score prognosis

Corresponding Author(s): Kunwei Shen

Just Accepted Date: 27 September 2020 Online First Date: 07 December 2020 Issue Date: 23 September 2021

Cite this article:

Jiayi Wu,Weiqi Gao,Xiaosong Chen, et al. Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients[J]. Front. Med., 2021, 15(4): 621-628.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-020-0738-0
https://academic.hep.com.cn/fmd/EN/Y2021/V15/I4/621

Tab.1 Pathology of 800 eligible patients

Tab.2 Distribution of RS according to clinico-pathological factors

Tab.3 Univariate prognostic analysis of 4-year IDFS, DDFS, and OS rates

Fig.1 Kaplan–Meier analysis of IDFS according to RS categories.

Tab.4 Multivariate prognostic analysis of IDFS, DDFS, and OS

Fig.2 Kaplan–Meier analysis of DDFS according to RS categories.

Fig.3 Kaplan–Meier analysis of OS according to RS categories.

1	S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817–2826 https://doi.org/10.1056/NEJMoa041588 pmid: 15591335
2	S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, D Watson, J Bryant, JP Costantino, CE Geyer Jr, DL Wickerham, N Wolmark. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24(23): 3726–3734 https://doi.org/10.1200/JCO.2005.04.7985 pmid: 16720680
3	KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, P Ravdin, R Bugarini, FL Baehner, NE Davidson, GW Sledge, EP Winer, C Hudis, JN Ingle, EA Perez, KI Pritchard, L Shepherd, JR Gralow, C Yoshizawa, DC Allred, CK Osborne, DF; Breast Cancer Intergroup of North America Hayes. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11(1): 55–65 https://doi.org/10.1016/S1470-2045(09)70314-6 pmid: 20005174
4	JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, CE Geyer Jr, EC Dees, EA Perez, JA Olson Jr, J Zujewski, T Lively, SS Badve, TJ Saphner, LI Wagner, TJ Whelan, MJ Ellis, S Paik, WC Wood, P Ravdin, MM Keane, HL Gomez Moreno, PS Reddy, TF Goggins, IA Mayer, AM Brufsky, DL Toppmeyer, VG Kaklamani, JN Atkins, JL Berenberg, GW Sledge. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373(21): 2005–2014 https://doi.org/10.1056/NEJMoa1510764 pmid: 26412349
5	JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, CE Geyer Jr, EC Dees, MP Goetz, JA Olson Jr, T Lively, SS Badve, TJ Saphner, LI Wagner, TJ Whelan, MJ Ellis, S Paik, WC Wood, PM Ravdin, MM Keane, HL Gomez Moreno, PS Reddy, TF Goggins, IA Mayer, AM Brufsky, DL Toppmeyer, VG Kaklamani, JL Berenberg, J Abrams, GW Sledge Jr. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379(2): 111–121 https://doi.org/10.1056/NEJMoa1804710 pmid: 29860917
6	J Hornberger, MD Alvarado, C Rebecca, HR Gutierrez, TM Yu, WJ Gradishar. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104(14): 1068–1079 https://doi.org/10.1093/jnci/djs261 pmid: 22767204
7	LN Harris, N Ismaila, LM McShane, F Andre, DE Collyar, AM Gonzalez-Angulo, EH Hammond, NM Kuderer, MC Liu, RG Mennel, C Van Poznak, RC Bast, DF; American Society of Clinical Oncology Hayes. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34(10): 1134–1150 https://doi.org/10.1200/JCO.2015.65.2289 pmid: 26858339
8	G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, MM Regan, M Piccart-Gebhart, HJ Senn, B Thürlimann, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017; F André, J Baselga, J Bergh, H Bonnefoi, SY Brucker, F Cardoso, L Carey, E Ciruelos, J Cuzick, C Denkert, A Di Leo, B Ejlertsen, P Francis, J Galimberti, V Garber, B Gulluoglu, P Goodwin, N Harbeck, DF Hayes, CS Huang, J Huober, K Hussein, J Jassem, Z Jiang, P Karlsson, M Morrow, R Orecchia, O Osborne, KC Pagani, AH Partridge, K Pritchard, J Ro, EJT Rutgers, F Sedlmayer, V Semiglazov, Z Shao, I Smith, M Toi, A Tutt, G Viale, T Watanabe, TJ Whelan, B Xu. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28(8): 1700–1712 https://doi.org/10.1093/annonc/mdx308 pmid: 28838210
9	MB Amin, SB Edge, FL Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, CC Compton, KR Hess, DC Sullivan, JM Jessup, JD Brierley, LE Gaspar, RL Schilsky, CM Balch, DP Winchester, EA Asare, M Madera, DM Gress, LR Meyer. AJCC Cancer Staging Manual. New York: Springer International Publishing, 2017
10	MN Levine, JA Julian, PL Bedard, A Eisen, ME Trudeau, B Higgins, L Bordeleau, KI Pritchard. Prospective evaluation of the 21-gene recurrence score assay for breast cancer decision-making in ontario. J Clin Oncol 2016; 34(10): 1065–1071 https://doi.org/10.1200/JCO.2015.62.8503 pmid: 26598746
11	M Tsai, S Lo, W Audeh, R Qamar, R Budway, E Levine, P Whitworth, B Mavromatis, R Zon, D Oldham, S Untch, T Treece, L Blumencranz, H Soliman. Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay. JAMA Oncol 2018; 4(1): e173470 https://doi.org/10.1001/jamaoncol.2017.3470 pmid: 29075751
12	M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, M Ellis, NL Henry, JC Hugh, T Lively, L McShane, S Paik, F Penault-Llorca, L Prudkin, M Regan, J Salter, C Sotiriou, IE Smith, G Viale, JA Zujewski, DF; International Ki-67 in Breast Cancer Working Group Hayes. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103(22): 1656–1664 https://doi.org/10.1093/jnci/djr393 pmid: 21960707
13	AC Wolff, ME Hammond, DG Hicks, M Dowsett, LM McShane, KH Allison, DC Allred, JM Bartlett, M Bilous, P Fitzgibbons, W Hanna, RB Jenkins, PB Mangu, S Paik, EA Perez, MF Press, PA Spears, GH Vance, G Viale, DF; Hayes American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31(31): 3997–4013 https://doi.org/10.1200/JCO.2013.50.9984 pmid: 24101045
14	J Wu, Y Fang, L Lin, X Fei, W Gao, S Zhu, Y Zong, X Chen, O Huang, J He, L Zhu, W Chen, Y Li, K Shen. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget 2017; 8(24): 38706–38716 https://doi.org/10.18632/oncotarget.16313 pmid: 28404972
15	CA Hudis, WE Barlow, JP Costantino, RJ Gray, KI Pritchard, JA Chapman, JA Sparano, S Hunsberger, RA Enos, RD Gelber, JA Zujewski. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25(15): 2127–2132 https://doi.org/10.1200/JCO.2006.10.3523 pmid: 17513820
16	LJ Goldstein, R Gray, S Badve, BH Childs, C Yoshizawa, S Rowley, S Shak, FL Baehner, PM Ravdin, NE Davidson, GW Sledge Jr, EA Perez, LN Shulman, S Martino, JA Sparano. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26(25): 4063–4071 https://doi.org/10.1200/JCO.2007.14.4501 pmid: 18678838
17	P Eifel, JA Axelson, J Costa, J Crowley, Jr Curran WJ, A Deshler, S Fulton, CB Hendricks, M Kemeny, AB Kornblith, TA Louis, M Markman, R Mayer, D Roter. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93(13): 979–989 https://doi.org/10.1093/jnci/93.13.979 pmid: 11438563
18	RW Carlson, SB Edge, RL Theriault; NCCN Breast Cancer Practice Guidelines Panel. NCCN: breast cancer. Cancer Control 2001; 8(6 Suppl 2): 54–61 pmid: 11760559
19	JA Sparano, S Paik. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26(5): 721–728 https://doi.org/10.1200/JCO.2007.15.1068 pmid: 18258979
20	H Pan, R Gray, J Braybrooke, C Davies, C Taylor, P McGale, R Peto, KI Pritchard, J Bergh, M Dowsett, DF Hayes; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017; 377(19):1836–1846 https://doi.org/10.1056/NEJMoa1701830 pmid: 29117498

[1]

FMD-19047-OF-SKW_suppl_1

Download

[1]	Xueping Li, Yuting Dai, Bing Chen, Jinyan Huang, Saijuan Chen, Lu Jiang. Clinical significance of CD34⁺CD117^dim/CD34⁺CD117^bri myeloblast-associated gene expression in t(8;21) acute myeloid leukemia[J]. Front. Med., 2021, 15(4): 608-620.
[2]	Yanfei Zhang, Xinchun Zhao, Yongchun Zhou, Min Wang, Guangbiao Zhou. *Identification of an E3 ligase-encoding gene RFWD3* in non-small cell lung cancer**[J]. Front. Med., 2020, 14(3): 318-326.
[3]	Huanping Wang, Haitao Meng, Jinghan Wang, Yinjun Lou, Yile Zhou, Peipei Lin, Fenglin Li, Lin Liu, Huan Xu, Min Yang, Jie Jin. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China[J]. Front. Med., 2020, 14(3): 327-334.
[4]	Yue Wang, Jinxia Zhang, Yunfan Wang, Shufang Wang, Yu Zhang, Qi Miao, Fei Gao, Huiying He. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma[J]. Front. Med., 2019, 13(6): 730-740.
[5]	Wenjing Wang, Shigang Ding, Hejun Zhang, Jun Li, Jun Zhan, Hongquan Zhang. G protein-coupled receptor LGR6 is an independent risk factor for colon adenocarcinoma[J]. Front. Med., 2019, 13(4): 482-491.
[6]	Weiqi Rong, Yang Zhang, Lei Yang, Lin Feng, Baojun Wei, Fan Wu, Liming Wang, Yanning Gao, Shujun Cheng, Jianxiong Wu, Ting Xiao. Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma[J]. Front. Med., 2019, 13(2): 250-258.
[7]	Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma[J]. Front. Med., 2019, 13(1): 94-103.
[8]	Jing Yue, Bo Zhang, Mingyue Wang, Junning Yao, Yifan Zhou, Ding Ma, Lei Jin. Effect of antitubercular treatment on the pregnancy outcomes and prognoses of patients with genital tuberculosis[J]. Front. Med., 2019, 13(1): 121-125.
[9]	Bin Yang, Yan Yu, Jing Chen, Yan Zhang, Ye Yin, Nan Yu, Ge Chen, Shifei Zhu, Haiyan Huang, Yongqun Yuan, Jihui Ai, Xinyu Wang, Kezhen Li. Possibility of women treated with fertility-sparing surgery for non-epithelial ovarian tumors to safely and successfully become pregnant---a Chinese retrospective cohort study among 148 cases[J]. Front. Med., 2018, 12(5): 509-517.
[10]	Sasa Nie, Zhe Feng, Lihua Xia, Jiuxu Bai, Fenglin Xiao, Jian Liu, Li Tang, Xiangmei Chen. Risk factors of prognosis after acute kidney injury in hospitalized patients[J]. Front. Med., 2017, 11(3): 393-402.
[11]	Changlin Cao, Jingxian Gu, Jingyao Zhang. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases[J]. Front. Med., 2017, 11(2): 169-177.
[12]	Lei Huang,Aman Xu. Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination[J]. Front. Med., 2017, 11(1): 20-31.
[13]	Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis[J]. Front. Med., 2016, 10(2): 183-190.
[14]	Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[15]	Aixiu Qiao,Feng Gu,Xiaojing Guo,Xinmin Zhang,Li Fu. Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications[J]. Front. Med., 2016, 10(1): 33-40.

Viewed

Full text

Abstract

Cited

Shared

Discussed